Ohsu Knight Cancer Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Compassionate Use Ponatinib
- Conditions
- Philadelphia Chromosome Positive (Ph+) LeukemiasChronic Myeloid Leukemia
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT01549548
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Therapy to Prevent Sexual Pain in Breast Cancer Survivors
Phase 3
Completed
- Conditions
- MenopauseDyspareuniaVulvodyniaBreast Cancer
- Interventions
- Drug: Topical saline
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT01539317
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
MRI Assessment of Leukemia Response to Therapy
Completed
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- Device: 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT01537159
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
Phase 2
Completed
- Conditions
- Adult Alveolar Soft Part SarcomaAdult AngiosarcomaAdult Desmoplastic Small Round Cell TumorAdult Epithelioid HemangioendotheliomaAdult Epithelioid SarcomaAdult Extraskeletal Myxoid ChondrosarcomaAdult Extraskeletal OsteosarcomaAdult FibrosarcomaAdult LeiomyosarcomaAdult Liposarcoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Placebo Administration
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT01532687
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase 2
Completed
- Conditions
- Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
- Interventions
- Biological: ipilimumabOther: laboratory biomarker analysis
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT01498978
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
Phase 1
Withdrawn
- Conditions
- Squamous Cell Carcinoma of the SkinRecurrent Skin CancerRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityStage IVA Squamous Cell Carcinoma of the Lip and Oral CavityStage IVB Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Interventions
- Drug: placeboRadiation: radiation therapyProcedure: therapeutic conventional surgeryOther: laboratory biomarker analysis
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT01465815
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- Refractory Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT01441882
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy
Phase 2
Completed
- Conditions
- Breast Carcinoma
- Interventions
- Procedure: Management of Therapy ComplicationsOther: Questionnaire Administration
- First Posted Date
- 2011-08-24
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT01422408
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
Phase 2
Terminated
- Conditions
- Recurrent Adult Diffuse Large Cell LymphomaRecurrent Mantle Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular Lymphoma
- Interventions
- Biological: Ofatumumab
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT01397591
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Comparing Warm Versus Cool Temperature Water During Colonoscopy
Not Applicable
Completed
- Conditions
- Colonoscopy
- Interventions
- Procedure: Warm vs Cool water
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2012-05-25
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 175
- Registration Number
- NCT01322724
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
© Copyright 2025. All Rights Reserved by MedPath